Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11493223 | 0.96 | HPGD (0.43) | PARP1DAOHPGDCHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL7600678 | 0.92 | HSD11B1 (0.41) | PARP1HPGDELANECHRM1 | |
| SCHEMBL8177398 | 0.79 | TFPI2 (0.50) | PARP1ELANECHRM2 | |
| SCHEMBL13571389 | 0.73 | HPGD (0.46) | DAOHPGD | |
| SCHEMBL11431122 | 0.72 | DAO (0.60) | DAO | |
| SCHEMBL7603169 | 0.72 | CHRM2 (0.40) | DAOCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL444120 | 0.71 | DAO (0.58) | DAO | |
| SCHEMBL7594818 | 0.70 | MAPK1 (0.65) | HPGD | |
| SCHEMBL792991 | 0.70 | DAO (0.56) | DAO | |
| SCHEMBL14701887 | 0.70 | DAO (0.56) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | PARP1 1336/4885DAO 866/4885HPGD 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.